208 related articles for article (PubMed ID: 15044096)
1. Effect of exogenous E2F-1 on the expression of common chromosome fragile site genes, FHIT and WWOX.
Ishii H; Mimori K; Vecchione A; Sutheesophon K; Fujiwara T; Mori M; Furukawa Y
Biochem Biophys Res Commun; 2004 Apr; 316(4):1088-93. PubMed ID: 15044096
[TBL] [Abstract][Full Text] [Related]
2. Expression of FRA16D/WWOX and FRA3B/FHIT genes in hematopoietic malignancies.
Ishii H; Vecchione A; Furukawa Y; Sutheesophon K; Han SY; Druck T; Kuroki T; Trapasso F; Nishimura M; Saito Y; Ozawa K; Croce CM; Huebner K; Furukawa Y
Mol Cancer Res; 2003 Nov; 1(13):940-7. PubMed ID: 14638866
[TBL] [Abstract][Full Text] [Related]
3. A novel approach to simultaneously scan genes at fragile sites.
Willem P; Brown J; Schouten J
BMC Cancer; 2006 Aug; 6():205. PubMed ID: 16895604
[TBL] [Abstract][Full Text] [Related]
4. Fragile histidine triad protein, WW domain-containing oxidoreductase protein Wwox, and activator protein 2gamma expression levels correlate with basal phenotype in breast cancer.
Guler G; Huebner K; Himmetoglu C; Jimenez RE; Costinean S; Volinia S; Pilarski RT; Hayran M; Shapiro CL
Cancer; 2009 Feb; 115(4):899-908. PubMed ID: 19130459
[TBL] [Abstract][Full Text] [Related]
5. Study of FHIT and WWOX expression in mucoepidermoid carcinoma and adenoid cystic carcinoma of salivary gland.
Dincer N; Tezel GG; Sungur A; Himmetoglu C; Huebner K; Güler G
Oral Oncol; 2010 Mar; 46(3):195-9. PubMed ID: 20060354
[TBL] [Abstract][Full Text] [Related]
6. Expression of common chromosomal fragile site genes, WWOX/FRA16D and FHIT/FRA3B is downregulated by exposure to environmental carcinogens, UV, and BPDE but not by IR.
Thavathiru E; Ludes-Meyers JH; MacLeod MC; Aldaz CM
Mol Carcinog; 2005 Nov; 44(3):174-82. PubMed ID: 16187332
[TBL] [Abstract][Full Text] [Related]
7. Coordinate loss of fragile gene expression in pancreatobiliary cancers: correlations among markers and clinical features.
Bloomston M; Kneile J; Butterfield M; Dillhoff M; Muscarella P; Ellison EC; Melvin WS; Croce CM; Pichiorri F; Huebner K; Frankel WL
Ann Surg Oncol; 2009 Aug; 16(8):2331-8. PubMed ID: 19434452
[TBL] [Abstract][Full Text] [Related]
8. Concordant loss of fragile gene expression early in breast cancer development.
Guler G; Uner A; Guler N; Han SY; Iliopoulos D; McCue P; Huebner K
Pathol Int; 2005 Aug; 55(8):471-8. PubMed ID: 15998374
[TBL] [Abstract][Full Text] [Related]
9. Alterations of common chromosome fragile sites in hematopoietic malignancies.
Ishii H; Furukawa Y
Int J Hematol; 2004 Apr; 79(3):238-42. PubMed ID: 15168591
[TBL] [Abstract][Full Text] [Related]
10. Common fragile genes and digestive tract cancers.
Kuroki T; Tajima Y; Furui J; Kanematsu T
Surg Today; 2006; 36(1):1-5. PubMed ID: 16378185
[TBL] [Abstract][Full Text] [Related]
11. Oncosuppressor proteins of fragile sites are reduced in cervical cancer.
Giarnieri E; Zanesi N; Bottoni A; Alderisio M; Lukic A; Vecchione A; Ziparo V; Croce CM; Mancini R
Cancer Lett; 2010 Mar; 289(1):40-5. PubMed ID: 19700237
[TBL] [Abstract][Full Text] [Related]
12. Components of DNA damage checkpoint pathway regulate UV exposure-dependent alterations of gene expression of FHIT and WWOX at chromosome fragile sites.
Ishii H; Mimori K; Inageta T; Murakumo Y; Vecchione A; Mori M; Furukawa Y
Mol Cancer Res; 2005 Mar; 3(3):130-8. PubMed ID: 15798093
[TBL] [Abstract][Full Text] [Related]
13. Fragile genes as biomarkers: epigenetic control of WWOX and FHIT in lung, breast and bladder cancer.
Iliopoulos D; Guler G; Han SY; Johnston D; Druck T; McCorkell KA; Palazzo J; McCue PA; Baffa R; Huebner K
Oncogene; 2005 Feb; 24(9):1625-33. PubMed ID: 15674328
[TBL] [Abstract][Full Text] [Related]
14. Expression of fragile histidine triad (FHIT) and WW-domain oxidoreductase gene (WWOX) in nasopharyngeal carcinoma.
Chen X; Li P; Yang Z; Mo WN
Asian Pac J Cancer Prev; 2013; 14(1):165-71. PubMed ID: 23534718
[TBL] [Abstract][Full Text] [Related]
15. Roles of FHIT and WWOX fragile genes in cancer.
Iliopoulos D; Guler G; Han SY; Druck T; Ottey M; McCorkell KA; Huebner K
Cancer Lett; 2006 Jan; 232(1):27-36. PubMed ID: 16225988
[TBL] [Abstract][Full Text] [Related]
16. Common fragile site tumor suppressor genes and corresponding mouse models of cancer.
Drusco A; Pekarsky Y; Costinean S; Antenucci A; Conti L; Volinia S; Aqeilan RI; Huebner K; Zanesi N
J Biomed Biotechnol; 2011; 2011():984505. PubMed ID: 21318118
[TBL] [Abstract][Full Text] [Related]
17. Common chromosomal fragile sites and cancer: focus on FRA16D.
O'Keefe LV; Richards RI
Cancer Lett; 2006 Jan; 232(1):37-47. PubMed ID: 16242840
[TBL] [Abstract][Full Text] [Related]
18. The tumor suppressor Fhit acts as a repressor of beta-catenin transcriptional activity.
Weiske J; Albring KF; Huber O
Proc Natl Acad Sci U S A; 2007 Dec; 104(51):20344-9. PubMed ID: 18077326
[TBL] [Abstract][Full Text] [Related]
19. Expression of WWOX and FHIT is downregulated by exposure to arsenite in human uroepithelial cells.
Huang YC; Hung WC; Chen WT; Yu HS; Chai CY
Toxicol Lett; 2013 Jul; 220(2):118-25. PubMed ID: 23618899
[TBL] [Abstract][Full Text] [Related]
20. Cancer prevention and therapy in a preclinical mouse model: impact of FHIT viruses.
Ishii H; Vecchione A; Fong LY; Zanesi N; Trapasso F; Furukawa Y; Baffa R; Huebner K; Croce CM
Curr Gene Ther; 2004 Mar; 4(1):53-63. PubMed ID: 15032614
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
